```
Page 18, line 29, after "-Cys", insert -- [SEQ ID NO: 2] --.

Page 18, line 31, after "-Cys", insert -- [SEQ ID NO: 9] --.

Page 20, line 25, after "-Glu-)", insert -- [SEQ ID NO: 1] --.

Page 20, line 26, after "-Cys", insert -- [SEQ ID NO: 3] --.

Page 21, line 4, after "-Glu", insert -- [SEQ ID NO: 1] --.

Page 21, line 5, after "-Cys", insert -- [SEQ ID NO: 2] --.

Page 21, line 6, after "-Cys", insert -- [SEQ ID NO: 3] --.

Page 21, line 8, after "-Glu", insert -- [SEQ ID NO: 1] --.

Page 21, line 11, after "-Glu", insert -- [SEQ ID NO: 1] --.
```

Please enter the attached Abstract of the Disclosure on the attached page.

In the Claims

Add new claims 15-43 as follows.

- administering to said mammal with hypergastrinemia an effective amount of an immunogenic composition that reduces the circulating hormone, gastrin.
- 16. The method according to claim 15, wherein said immunogenic composition comprises a peptide conjugated to an immunogenic carrier and a pharmaceutically acceptable carrier.
- 17. The method according to claim 16, wherein said immunogenic composition is selected from the group consisting of a G17 peptide fragment SEQ ID NO: 1 linked by an amino acid spacer to an immunogenic carrier; a G34 peptide fragment SEQ ID NO: 2 linked by an amino acid spacer to an immunogenic carrier; a combination of said G17 and G34 fragments linked by an amino acid spacer to an

immunogenic carrier.

- 18. The method according to claim 17, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.
- 19. The method according to claim 15, wherein said composition comprises anti-gastrin antibodies that bind to gastrin.
- 20. The method according to claim 19, wherein said antibodies are purified or humanized.
- The method according to claim 19, wherein said antibodies bind to heptadecagastrin G17.
- 22. The method according to claim 19, wherein said antibodies bind to tetratriacontagastrin G34.
- The method according to claim 19, wherein said antibodies comprise a mixture of antibodies that bind to heptadecagastrin G17 and antibodies that bind to tetratriacontagastrin G34.
- 24. The method according to claim 15, further comprising administering to said mammal an agent selected from the group consisting of a histamine H₂ receptor blocker and a proton pump inhibitor.
- 25. The method according to claim 24, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.
 - 26. The method according to claim 24, wherein said inhibitor is

selected from the group consisting of omeprazole, lansoprazole and pantoprazole.

- 27. The method according to claim 24, wherein said mammal is administered said immunogenic composition before said agent.
- 28. The method according to claim 24, wherein said composition and agent are co-administered to said mammal.
- 29. The method according to claim 15, wherein said hypergastrinemia is associated with a condition selected from the group consisting of pernicious anemia, a gastric tumor, a gastric cancer, and a course of therapy with a substance that results in increased gastrin levels.

- 30. A method for reducing the side effects of anti-ulcer agents in a mammal comprising administering to a mammal receiving an agent that suppresses gastric acid production or secretion an effective amount of an immunogenic composition that reduces the circulating hormone, gastrin.
- 31. The method according to claim 30, wherein said immunogenic composition comprises a peptide conjugated to an immunogenic carrier and a pharmaceutically acceptable carrier.
- 32. The method according to claim 31, wherein said immunogenic composition is selected from the group consisting of a G17 peptide fragment SEQ ID NO: 1 linked by an amino acid spacer to an immunogenic carrier; a G34 peptide fragment SEQ ID NO: 2 linked by an amino acid spacer to an immunogenic carrier; a combination of said G17 and G34 fragments linked by an amino acid spacer to an immunogenic carrier.
- 33. The method according to claim 32, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.
- 34. The method according to claim 30, wherein said composition comprises anti-gastrin antibodies that bind to gastrin.
- 35. The method according to claim 34, wherein said antibodies are purified or humanized.
- 36. The method according to claim 34, wherein said antibodies bind to heptadecagastrin G17.

- 37. The method according to claim 34, wherein said antibodies bind to tetratriacontagastrin G34.
- " 38. The method according to claim 34, wherein said antibodies comprise a mixture of antibodies that bind to heptadecagastrin G17 and antibodies that bind to tetratriacontagastrin G34.
- 39. The method according to claim 30, wherein said agent is selected from the group consisting of a histamine H₂ receptor blocker and a proton pump inhibitor.
- 40. The method according to claim 39, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.
- 41. The method according to claim 39, wherein said inhibitor is selected from the group consisting of omeprazole, lansoprazole and pantoprazole.
- 42. The method according to claim 30, wherein said mammal is administered said immunogenic composition before said agent.
- 43. The method according to claim 30, wherein said composition and agent are co-administered to said mammal.

REMARKS

Upon entry of this preliminary amendment, the claims pending are claims 7 and 15-43. New claims 15-43 are supported throughout the specification and by original claims 1-14.

Specification pages 18, 20 and 21 are amended to insert SEQ ID NOS.